---
figid: PMC6000833__nihms959144f2
figtitle: New perspectives for targeting RAF kinase in human cancer
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC6000833
filename: nihms959144f2.jpg
figlink: /pmc/articles/PMC6000833/figure/F2/
number: F2
caption: 'a ∣ Structural features of representative RAF inhibitors bound to a BRAF
  dimer. The three structural types of RAF inhibitor bound to BRAF are shown as ribbon
  representations: Vemurafenib (VEM), a type I1/2 inhibitor (αC-OUT/DFG-IN), AZ628
  (AZ), a type II inhibitor (αC-IN/DFG-OUT), and SB590885 (SB), a type I inhibitor
  (αC-IN/DFG-IN). Vemurafenib and other type I1/2 inhibitors stabilize the αC-helix
  (red) of the first BRAF protomer to the OUT position and the αC-helix (green) of
  the second BRAF protomer to the IN position (Protein Data Bank (PDB) ID: 3OG7).
  AZ628 and other type II inhibitors stabilize the αC-helix of the first BRAF protomer
  (red) and the αC-helix of the second BRAF protomer (green) to the IN position (PDB
  ID: 4RZW). SB590885 and other type I inhibitors stabilize both the αC-helix of the
  first BRAF protomer (red) and the αC-helix of the second BRAF protomer (green) to
  the IN position (PDB ID: 2FB8). AZ628 and other type II inhibitors induce the DFG
  motif to an OUT conformation, while other inhibitors of the type I and I1/2 groups
  maintain the DFG in an IN conformation. b ∣ Schematic showing the αC-OUT RAF inhibitor-induced
  paradoxical RAF pathway activation and negative allostery. Most αC-OUT RAF inhibitors
  stabilize the αC-helix (indicated by the red wavy line in the kinase domain) in
  the overall OUT position (1). However, the C-terminal αC-helix residue R506 is displaced
  into the IN position, which promotes the interaction of RAF with RAS-GTP (2). Subsequently,
  RAF is primed through phosphorylation and dimerization. RAF inhibitor binding to
  one protomer and stabilization of the αC-helix in the OUT position sterically prevents
  inhibitor binding to the second monomer (negative allostery), leading to paradoxical
  pathway activity (3). c ∣ Schematic showing αC-IN RAF inhibitor-induced RAF activation
  and effective dimer inhibition. By stabilizing the αC-helix in the IN position (1),
  αC-IN RAF inhibitors promote the formation of the RAF–RAS–GTP complex (2). This
  is followed by RAF phosphorylation and dimerization. Due to low negative allostery,
  RAF inhibitors belonging to this group effectively bind and inhibit both protomers
  in the RAF dimer (3). INH, inhibitor; NTD, N-terminal domain.'
papertitle: New perspectives for targeting RAF kinase in human cancer.
reftext: Zoi Karoulia, et al. Nat Rev Cancer. 2017 Nov;17(11):676-691.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8747315
figid_alias: PMC6000833__F2
figtype: Figure
redirect_from: /figures/PMC6000833__F2
ndex: 2a0473e0-df1a-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6000833__nihms959144f2.html
  '@type': Dataset
  description: 'a ∣ Structural features of representative RAF inhibitors bound to
    a BRAF dimer. The three structural types of RAF inhibitor bound to BRAF are shown
    as ribbon representations: Vemurafenib (VEM), a type I1/2 inhibitor (αC-OUT/DFG-IN),
    AZ628 (AZ), a type II inhibitor (αC-IN/DFG-OUT), and SB590885 (SB), a type I inhibitor
    (αC-IN/DFG-IN). Vemurafenib and other type I1/2 inhibitors stabilize the αC-helix
    (red) of the first BRAF protomer to the OUT position and the αC-helix (green)
    of the second BRAF protomer to the IN position (Protein Data Bank (PDB) ID: 3OG7).
    AZ628 and other type II inhibitors stabilize the αC-helix of the first BRAF protomer
    (red) and the αC-helix of the second BRAF protomer (green) to the IN position
    (PDB ID: 4RZW). SB590885 and other type I inhibitors stabilize both the αC-helix
    of the first BRAF protomer (red) and the αC-helix of the second BRAF protomer
    (green) to the IN position (PDB ID: 2FB8). AZ628 and other type II inhibitors
    induce the DFG motif to an OUT conformation, while other inhibitors of the type
    I and I1/2 groups maintain the DFG in an IN conformation. b ∣ Schematic showing
    the αC-OUT RAF inhibitor-induced paradoxical RAF pathway activation and negative
    allostery. Most αC-OUT RAF inhibitors stabilize the αC-helix (indicated by the
    red wavy line in the kinase domain) in the overall OUT position (1). However,
    the C-terminal αC-helix residue R506 is displaced into the IN position, which
    promotes the interaction of RAF with RAS-GTP (2). Subsequently, RAF is primed
    through phosphorylation and dimerization. RAF inhibitor binding to one protomer
    and stabilization of the αC-helix in the OUT position sterically prevents inhibitor
    binding to the second monomer (negative allostery), leading to paradoxical pathway
    activity (3). c ∣ Schematic showing αC-IN RAF inhibitor-induced RAF activation
    and effective dimer inhibition. By stabilizing the αC-helix in the IN position
    (1), αC-IN RAF inhibitors promote the formation of the RAF–RAS–GTP complex (2).
    This is followed by RAF phosphorylation and dimerization. Due to low negative
    allostery, RAF inhibitors belonging to this group effectively bind and inhibit
    both protomers in the RAF dimer (3). INH, inhibitor; NTD, N-terminal domain.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Sb
  - Raf
  - ras
  - Ras64B
  - Ras85D
  - ATPsynbeta
  - Atpalpha
  - Dsor1
  - Mtk
  - Erk7
  - rl
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - KRAS
  - HRAS
  - NRAS
  - FUZ
  - ATP8A2
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
---
